Skip to main navigation

Skip to content

Search for:

About
Technology
Pipeline
Products
- XIPERE®
Investors

Investor Menu

IR Overview
News
Events and Presentations
Governance
SEC Filings
Financial Info
Resources

News

Year

Aug 9 2022

Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 8 2022

Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million

Aug 3 2022

Clearside Biomedical to Participate in Three Upcoming Investor Conferences in August 2022

Jul 27 2022

Clearside Biomedical to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Tuesday, August 9, 2022

Jul 26 2022

Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients

Jul 7 2022

Clearside Biomedical Suprachoroidal Delivery Technology to be Featured at Upcoming ASRS and OIS Medical Meetings

Jun 14 2022

Clearside Biomedical Expands Leadership Team with Appointment of Susan Coultas, Ph.D., as Chief Clinical Officer

Jun 8 2022

Clearside Biomedical to Participate in the JMP Securities Life Sciences Conference

May 11 2022

Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update

May 5 2022

Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technology

Current page 1
Page 2
Next page
Last page

Email Alerts
Print Page
RSS Feeds
IR Contact

Request Email Alerts

(678) 270-3631
info@clearsidebio.com
CONTACT US

ABOUT US
MANAGEMENT
BOARD OF DIRECTORS
SCIENTIFIC ADVISORY BOARD
PRIVACY POLICY

SCIENCE
SUPRACHOROIDAL SPACE
SCS MICROINJECTOR®
PUBLICATIONS & PRESENTATIONS
Intellectual Property

PRODUCTS
XIPERE™

PIPELINE
CLS-AX
INTEGRIN INHIBITOR
GENE THERAPY
COLLABORATIONS

INVESTORS
IR OVERVIEW
NEWS
EVENTS & PRESENTATIONS
GOVERNANCE
SEC FILINGS
FINANCIAL INFO
RESOURCES

Copyright 2022 © Clearside Biomedical | Website Design and Development by Emma Tang Designs